Evidence map›Paper›PMID 39144559›Full record

ArticleACS pharmacology & translational science2024

Epigenetic Targeting of Heparan Sulfate 3-

Nico Bückreiß, Marie Schulz-Fincke, Philipp König, Marco Maccarana, Toin H van Kuppevelt, Jin-Ping Li, Martin Götte, Gerd Bendas

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS pharmacology & translational science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Nico BückreißPharmaceutical Institute, Pharmaceutical and Cell Biological Chemistry, University of Bonn, 53121 Bonn, Germany.
Marie Schulz-FinckePharmaceutical Institute, Pharmaceutical and Cell Biological Chemistry, University of Bonn, 53121 Bonn, Germany.
Philipp KönigPharmaceutical Institute, Pharmaceutical and Cell Biological Chemistry, University of Bonn, 53121 Bonn, Germany.
Marco MaccaranaDepartment of Medical Biochemistry and Microbiology, SciLifeLab Uppsala, The Biomedical Center, University of Uppsala, 75123 Uppsala, Sweden.
Toin H van KuppeveltDepartment of Biochemistry, Nijmegen Center for Molecular Life Sciences, Radboud University Nijmegen Medical Center, 6500 HB Nijmegen, The Netherlands.
Jin-Ping LiDepartment of Medical Biochemistry and Microbiology, SciLifeLab Uppsala, The Biomedical Center, University of Uppsala, 75123 Uppsala, Sweden.
Martin GötteDepartment of Gynecology and Obstetrics, Münster University Hospital, Vesaliusweg 2-4, 48149 Münster, Germany.
Gerd BendasPharmaceutical Institute, Pharmaceutical and Cell Biological Chemistry, University of Bonn, 53121 Bonn, Germany.ORCID https://orcid.org/0000-0002-8667-7201

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The deregulation of cell surface heparan sulfate proteoglycans (HSPGs) is a main issue of cancer cells for increasing their malignancy. In these terms, the sulfation pattern of HS, created by an orchestrated activity of enzymes balancing a site-specific sulfation, is of key importance. These enzymes are often deregulated by epigenetic processes in cancer, e.g., being silenced by DNA hypermethylation. Here, we address this issue in human breast cancer cell lines aiming to target epigenetic processes to reactivate HS sulfation, shifting HS into an antithrombotic phenotype for which 3-

Identifiers

PMID39144559
PMCPMC11320729

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.